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Severe acute respiratory syndrome (SARS) is an
infectious disease caused by a newly identified human
coronavirus (SARS-CoV). Currently, no effective drug
exists to treat SARS-CoV infection. In this study, we inves-
tigated whether a panel of commercially available antiviral
drugs exhibit in vitro anti–SARS-CoV activity. A drug-
screening assay that scores for virus-induced cytopathic
effects on cultured cells was used. Tested were 19 clinical-
ly approved compounds from several major antiviral phar-
macologic classes: nucleoside analogs, interferons,
protease inhibitors, reverse transcriptase inhibitors, and
neuraminidase inhibitors. Complete inhibition of cytopathic
effects of SARS-CoV in culture was observed for interferon
subtypes, β-1b, α-n1, α-n3, and human leukocyte interfer-
on a. These findings support clinical testing of approved
interferons for the treatment of SARS.
S
evere acute respiratory syndrome (SARS) (1,2) is an
infectious disease caused by a newly identified human
coronavirus (SARS-CoV) (3,4). The disease can produce
severe pneumonia with a reported fatal outcome of 15% to
20%. Currently, no effective drug exists to treat SARS-
CoV infection (5). The urgency of the outbreak has led to
the empiric use of broad- spectrum antibiotics and antivi-
ral agents in affected patients in several countries (6–12).
Intensive efforts are under way to gain more insight into
the mechanisms of viral replication, in order to develop
targeted antiviral therapies and vaccines. Developing
effective and safe vaccines and chemotherapeutic agents
against SARS CoV, however, may take years.
The recent epidemic has shown that knowledge is lack-
ing regarding the clinical management and treatment of
infected patients. Ribavirin (6–12), oseltamivir (8–10), fos-
carnet (8), intravenous immunoglobulin (8), and other
agents have been used to treat patients. Preliminary results
from in vitro testing indicate that ribavirin concentrations
that inhibit other viruses sensitive to ribavirin do not inhibit
replication or cell-to-cell spread of the SARS-CoV (5).
However, the U.S. Centers for Disease Control and
Prevention concluded that further in vitro testing of antiviral
drugs on other coronavirus isolates and more information on
the clinical outcome of patients treated with ribavirin or
other antiviral drugs in controlled trials is needed (5).
The aim of this study was to investigate whether a panel
of currently available antiviral agents exhibit in vitro
anti–SARS-CoV activity. Three general antiviral strategies
are generally found (13): 1) direct antiviral effects, 2) inhi-
bition of viral entry and replication at the cellular level by
targeting virus-related processes, and 3) enhancement of
host immune response. A total of 19 drugs approved for
clinical use in the treatment of viral infections were tested
in this study. They are representative compounds from
major antiviral pharmacologic classes that are currently
commercially available: nucleoside analogs, interferons,
protease inhibitors, reverse transcriptase inhibitors and
neuraminidase inhibitors. 
Acell-based assay utilizing cytopathic endpoints (CPE)
was set up using Vero E6 cells to screen these antiviral
compounds. SARS-CoV has been shown to infect Vero E6
cells, an African green monkey kidney cell line (3), and
this remains the only in vitro model of SARS-CoV infec-
tion. The initial screen was followed by a plaque reduction
assay to determine the 50% effective concentration (EC50)
of compounds showing positive results. These experiments
allow rapid screening of commercially available antiviral
agents, enabling those with in vitro evidence of activity to
move expeditiously into clinical studies, since safety and
pharmacokinetic information in humans is already avail-
able for other disease indications. 
Here we report that certain interferon subtypes exhibit
in vitro inhibitory activity against SARS-CoV and are can-
didates for follow-up studies in animal models and patients
to determine their efficacy in vivo. 
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Selection and Preparation of Drugs 
To rapidly identify a pharmacologic agent that could be
used to treat SARS, a collection of antiviral drugs was test-
ed against SARS-CoV, the etiologic agent of the atypical
pneumonia. To investigate a wide spectrum of potential
molecular targets, we decided to cover the entire pharma-
cologic range of commercially available antiviral agents,
including agents not expected to be active against coron-
aviruses. Information on antiviral drugs provided here was
obtained from prescribing information sheets or from com-
munications with the manufacturer. 
Nucleoside analogues are a diverse class of com-
pounds; in general, they inhibit viral RNA or DNA poly-
merases or other enzymes, interfering with nucleic acid
synthesis. In this study, the selected compounds that target
DNAviruses such as herpes simplex virus (HSV) and vari-
cella-zoster viruses (VZV) were acyclovir, ganciclovir,
and foscarnet. Ribavirin has activity against a range of
DNA and RNA viruses; in different cell lines, ED50 ranges
from 1 to 100 µg/mL. Antiretroviral (HIV) drugs include
reverse transcriptase (RT) inhibitors and protease
inhibitors. Selected HIV nucleoside RT inhibitors studied
were zidovudine and lamivudine, while HIV protease
inhibitors studied were indinavir, nelfinavir, and
saquinavir. The third group of antivirals studied were the
neuraminidase inhibitors, both commercially available
preparations, zanamivir and oseltamivir were used in this
study. Interferons were the next major class of antivirals
studied. Various subtypes of interferon α (2a, 2b, n1, and
n3, human leukocyte) and β (1a and 1b) were used.
Amantadine, an old antiviral compound, was also studied.
Different terms have been used to express antiviral activi-
ty, namely, EC50, 95% effective concentration (EC95), and
50% inhibitory concentration (IC50); Table 1 illustrates the
range of activity against selected viruses. 
Tenfold dilutions of the drug were tested to cover a
broad range of concentrations above and below inhibitory
dosages as reported by the manufacturer for other viral-
host combinations. Compounds already present in aqueous
injections were made up to volume by using Hank’s
buffered saline solution. For tablet and capsule formula-
tions with soluble active ingredients, the outer coat was
removed wherever applicable, and the preparation was
ground in a mortar and pestle. The contents were dissolved
in water, vortexed, and centrifuged thereafter at 3,000 g.
The required volume was pipetted from the supernatant
and diluted accordingly. When the active ingredients were
insoluble in water (nelfinavir and saquinavir), the contents
were dissolved in dimethylsulphoxide (DMSO); care was
taken to ensure that the final concentration of DMSO in the
dilutions would not exceed 1%. For plaque assays, fivefold
drug dilutions were prepared by using growth media as
specified below.
SARS-CoV Production and Infection 
Vero E6 cells (American Type Culture Collection,
Manassas, VA) were propagated in 75 cm2 cell culture
flasks in growth medium consisting of medium 199
(Sigma, St Louis, MO) supplemented with 10% fetal calf
serum (FCS; Biological Industries, Kibbutz Beit Haemek,
Israel). SARS-CoV 2003VA2774 (an isolate from a SARS
patient in Singapore), which has been previously
sequenced (14), was propagated in Vero E6 cells. Briefly,
2 mLof stock virus was added to a confluent monolayer of
Vero E6 cells and incubated at 37°C in 5% CO2 for 1 h; 13
mL of medium 199 supplemented with 5% FCS was then
added. The cultures were incubated at 37°C in 5% CO2,
and the supernatant was harvested after 48 h; in >75% of
cultures, inhibition of CPE (3+) in each well was observed
with an inverted microscope. The supernatant was clarified
at 2,500 rpm and then divided into aliquots, placed in cry-
ovials, and stored at –80°C until use. 
Virus Handling and Titration 
All virus culture and assays were carried out in the
biosafety level-3 laboratory at the Environmental Health
Institute, according to the conditions set out in Biosafety in
Microbiological and Biomedical Laboratories (15). Virus
titer in the frozen culture supernatant was determined by
using a plaque assay. Briefly, 100 µL of virus in 10-fold
serial dilution was added, in duplicates, to a monolayer of
Vero E6 cells in a 24-well plate. After 1 h of incubation at
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Table 1. Examples of inhibitory concentrations of antiviral drugs 
against selected viruses
a 
Compound  IC50  Virus 
Foscavir  50–800 µmol/L  Cytomegalovirus 
  5–443 µmol/L  Herpes simplex mutants 
Acyclovir  0.01–13.5 µg/mL  Herpes smplex virus and 
varicella-zoster virus 
Cymevene  0.02–3.48 µg/mL  Laboratory strains or clinical 
isolates of cytomegalovirus 
Ribavirin  1–25 µg/mL  Influenza 
  25–100 µg/mL  HIV and other retroviruses 
  3.2–50 µg/mL (MIC)  Herpes and poxviruses 
suppression 
Lamivudine  0.0006–0.034 µg/mL  HIV 
Zidovudine  0.003–0.013 µg/mL  HIV 
Fortovase  1–30 nmol/L  HIV 
Viracept  7–196 nM (EC95)  HIV 
Crixivan  25–100 nmol/L  HIV 
Relenza  0.005–16 µmol  Influenza virus 
Tamiflu  0.0008 µM–>35 µmol  Influenza virus 
Amantadine  0.1–25 (ED50)  Influenza virus 
aIC50, 50% inhibitory concentration; EC95, 95% effective concentration; ED50, 50%
effective dose. 
 37°C in 5% CO2, the viral inoculum was aspirated, and 1
mL of carboxymethylcellulose overlay with medium 199,
supplemented with 5% FCS, was added to each well. After
4 days of incubation, the cells were fixed with 10% forma-
lin and stained with 2% crystal violet. The plaques were
counted visually, and the virus titer in plaque-forming
units per mL (PFU/mL) was calculated. 
Cytopathic Endpoint Assay 
The protocol used was adapted from Al-Jabri et al. (16),
and all drugs were tested in quadruplicate. Briefly, 100 µL
of serial 10-fold dilutions of the drugs were incubated with
100 µLof Vero E6 cells, giving a final cell count of 20,000
cells per well in a 96-well plate. The incubation period was
1 h at 37°C in 5% CO2, except for the interferons, which
were incubated overnight with the cells. Ten microlites of
virus at a concentration of 10,000 PFU/well was then
added to each of the test wells. The plates were incubated
at 37°C in 5% CO2 for 3 days and observed daily for CPE.
The end point was the drug dilution that inhibited 100% of
the CPE (CIA100) in quadruplicate wells. To determine
cytotoxicity, 100 µLof serial 10-fold dilutions of the drugs
was incubated with 100 µL of Vero E6 cells, giving a final
cell count of 20,000 cells per well in a 96-well plate, with-
out viral challenge. The plates were then incubated at 37°C
in 5% CO2 for 3 days and examined for toxicity effects by
using an inverted microscope. 
Plaque Reduction Assay 
Trypsinized Vero E6 cells were resuspended in growth
medium and preincubated with interferons (serial fivefold
dilution) in quadruplicate wells in 24-well plates. The next
day, the medium was aspirated, and 100 µL of virus was
added to each well at a titer of 100 PFU/well. After incu-
bation for 1 h, the virus inoculum was aspirated, and a car-
boxymethylcellulose overlay containing maintenance
medium and the appropriate interferon concentration was
added. After 4 days’ incubation, the plates were fixed and
stained as described previously. The number of plaques
was then counted visually, and the concentration of drug
that inhibits 50% of plaques in each well (IC50) was deter-
mined. Results were plotted in Microsoft Excel, and a
polynomial of order three was used to approximate the
data and extrapolate IC50 and IC95 values. 
Results
Cell-based Assay of SARS-CoV Infection 
High titers of infectious SARS-CoV, originally derived
from a respiratory sample of a SARS patient, were propa-
gated on Vero E6 cells. The CPE of SARS-CoV on Vero
E6 was evident within 24 hours after infection (Figure 1).
SARS-CoV–infected cells display a CPE characterized by
the appearance of rounded cells and the destruction of the
monolayer. 
Antiviral Drug Activity 
A collection of 19 antiviral drugs was tested in the
SARS-CoV CPE inhibition assay (Table 2). The set of
drugs tested included seven interferons, five nucleoside
analogs, three protease inhibitors, two RT inhibitors, and
two neuraminidase inhibitors. Complete inhibition of the
CPE was observed for four of the seven interferons in the
initial screen when very high viral challenge of 104
PFU/well and a high multiplicity of infection (MOI = 0.5)
rate were used. Complete inhibition, expressed as CIA100,
was observed for interferon β-1b (Betaferon) at 5,000
IU/mL, interferon α-n3 (Alferon) at 5,000 IU/mL, interfer-
on α-n1 (Wellferon) at 250,000 IU/mL, and human leuko-
cyte interferon α (Multiferon) at 500,000 IU/mL.
Ribavirin also completely inhibited the CPE at 5,000
µg/mL (Table 3). None of the other drugs showed com-
plete inhibition of CPE, even at the highest concentration
of drug tested (Table 2).
Rebif (IFN-β-1a) showed slight inhibition of CPE at
250,000 IU/mL, but the inhibition was not complete at the
screening virus load of 10,000 PFU/well. Likewise,
Roferon (IFN-α-2a) showed slight, incomplete inhibition
at 50,000 IU/mL. Because the criteria for ascertaining anti-
SARS-CoV activity in this screen were set at 100% inhibi-
tion of CPE, and as high doses of interferons may result in
severe clinical side effects, we chose to conduct further
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004 583
SARS Coronavirus and Antiviral Drugs
Figure 1. Microscopic appear-
ance of control (A) and infected
(B) Vero E6 cells, demonstrating
cytopathic effects.evaluations only in the interferons that showed complete
inhibition from initial screen, namely, Wellferon, Multi-
feron, Betaferon, and Alferon.
Based upon results of the primary screen, the four
active interferons and ribavirin were retested at two lower
viral challenges, 103 and 102 PFU/ well. All four drugs
again showed inhibitory effect, although the CIA100 were
dependent on viral loads (Table 3). At the lowest viral load
the CIA100  were 5 IU/mL for both interferon β-1b
(Betaferon) and human leukocyte interferon α
(Multiferon); and 50 and 250 IU/mL for interferon α-n3
(Alferon) and interferon α-n1 (Wellferon), respectively.
No cytotoxicity of the interferons was observed at or near
inhibitory concentrations. Ribavirin showed inhibitory
activity at all three viral loads, but only at high concentra-
tions of the drug, 0.5–5 mg/mL. At high concentrations of
ribavirin (0.2–1 mg/mL) cytotoxic effects were observed
on VeroE6 cells, as has been reported for other cell types
(17,18). As such, we consider ribavirin to be inactive
against SARS-CoV.
A plaque reduction assay format with 100 PFU of
SARS-CoV (MOI = 0.0005) was conducted to determine
the IC50 for Betaferon, Alferon, and Multiferon, the three
compounds that showed greatest potency for inhibition of
CPE. Additional supply was not available for testing inter-
feron  α-n1 (Wellferon), as production of this drug has
been discontinued. Cells were preincubated for 15 h with
fivefold dilutions of drug. Viral-induced plaques, which
developed in 3 days, were counted to determine the
inhibitory effect of the drugs at various concentrations. All
three interferon preparations displayed a dose-dependent
inhibition of SARS-CoV plaque formation in this assay
(Figure 2). The IC50 and IC95 were determined to be 0.2
and 8 IU/mL for Betaferon, 0.8 and 200 IU/mL for
Alferon, and 2 and 44 IU/mL for Multiferon.
Discussion
Betaferon, Alferon, Multiferon, Wellferon, and rib-
avirin inhibited CPE in SARS-CoV–infected Vero E6
cells, in decreasing order of potency. Ribavirin, a drug
widely used in initial efforts to manage SARS infections,
inhibited CPE completely at 500–5,000 µg/mL at virus
loads of 100–10,000 PFU per well. The concentration
range observed is much higher than concentrations that
inhibit other viruses (respiratory syncytial virus, ED50 2–8
µg/mL, HIV or resistant strains of rhinovirus, 50–100
µg/mL), including viruses that were tested on Vero cells
(West Nile virus, New York isolate 178 µg/mL, and
Uganda isolate 41 µg/mL) (19). In addition, the CPE
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Table 3. Complete inhibition of cytopathic effect (CIA100) at 
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Table 2. Commercially available antiviral agents tested, source and starting concentration 
Antiviral agent  Source  Highest concentration tested  Inhibition of cytopathic effect (CIA100) 
Interferons 
Interferon α-2a (Roferon)  Roche  100,000 IU/mL  No 
Interferon α-2b (Intron A)  Schering-Plough  500,000 IU/mL  No 
Interferon α-n1 (Wellferon)  GlaxoSmithKline  500,000 IU/mL  Yes 
Interferon α-n3 (Alferon)  Hemispheryx  10,000 IU/mL  Yes 
Interferon β-1a (Rebif)  Serono  500,000 IU/mL  No 
Interferon β-1b (Betaferon)  Schering AG  100,000 IU/mL  Yes 
Nucleoside analogs 
Acyclovir   Faulding  1,000 µg/mL  No 
Ganciclovir  (Cymevene)   Roche  50,000 µg/mL  No 
Ribavirin  ICN Pharma  10,000 µg/mL  Yes 
Protease inhibitors 
Indinavir (Crixivan)  Merck  100 µmol/L  No 
Nelfinavir (Viracept)  Roche  10,000 nmol/L  No 
Saquinavir (Fortovase)  Roche  10,000 nmol/L  No 
Reverse transcriptase inhibitors 
Lamivudine (Epivir)  GlaxoSmithKline  1,000 µmol/L  No 
Zidovudine (Retrovir)  GlaxoSmithKline  1,000 µg/mL  No 
Neuraminidase inhibitors 
Oseltamivir (Tamiflu)  Roche  10,000 µmol/L  No 
Zanamivir (Relenza)  GlaxoSmithKline  1,000 µmol/L  No 
Other 
Amantadine (Symmetrel)  Novartis  1,000 µg/mL  No 
Foscarnet (Foscavir)  AstraZeneca  8,000 µmol/L  No inhibitory concentrations obtained in this study were
above the cytotoxic concentration range against Vero cells.
The 50% cytotoxic dose (CD50) on various cell lines has
been reported to be approximately 200–1000 µg/mLof rib-
avirin (17,18). We observed slight cytotoxicity by micro-
scopic examination of the cells, making it difficult to
accurately obtain in vitro efficacy data against SARS-CoV.
It appears that due to the low activity of ribavirin in vitro,
inhibitory doses may not be achievable clinically. It is pos-
sible that ribavirin would be more effective in combination
with interferons. Combination therapy with ribavirin and
interferon α has now become standard treatment for chron-
ic hepatitis C (20–22). Additionally, we have tested the
effect of ribavirin and Betaferon in combination (range of
concentration of ribavirin, 1–100 µg/mL; range of concen-
tration of Betaferon, 0.1–10 IU/mL). At 1,000 PFU, this
combination did not demonstrate observable synergistic
inhibitory effect against SARS-CoV. 
This study describes in vitro activity of four interferon
subtypes against the SARS-CoV. Interferons have been
used as anticancer and antiviral agents, in particular, for
treating hepatitis B and C infections. Various groups have
reported the clinical benefit of intranasally administered
interferon α in human volunteers before and after inocula-
tion with non-SARS coronaviruses (23–25). The antiviral
activity of interferons is mediated by direct effects on
infected cells or by modulating an immune response (26).
Interferons interact with specific surface cell receptors,
leading to production of interferon-stimulated gene prod-
ucts such as 2′5′-oligoadenylate synthase and protein
kinase PKR (27). 
In SARS-CoV infection, a convenient starting point for
the use of interferons against a SARS-CoV infection
would be the usual clinical doses for the treatment of hep-
atitis B or C. Common clinical dosages for interferon α
range from 3 to 5 million IU three times a week to 5 mil-
lion IU daily. For interferon β, data regarding efficacy in
the treatment of hepatitis C are conflicting, and interferon
β (at doses of 3 to 6 million IU three times weekly) is usu-
ally only used in the treatment of infections in patients
whose condition no longer responds to other therapies.
Plasma levels of interferons administered through the sub-
cutaneous route are usually low with correspondingly
short half-lives. In view of their mechanism of action,
absolute serum levels may not be meaningful as a measure
of the biologic activity of interferons, compared to the
induction of cellular products such as 2′5′ oligoadenylate
synthase.
Interferon activity varies among different cell types
(28,29), however. Specific interferon subtypes which
inhibit SARS-CoV in Vero cells may not necessarily have
the same effect in other cells; the converse may also be
true—that those drugs that are negative in Vero cells may
be effective in other cell types. We are currently identify-
ing other in vitro models of SARS-CoV infection that will
enable us to address cell-type specific drug effects. Also,
interferon subtypes exhibited different activity against
SARS-CoV in this study. The mechanism for the differ-
ence in activity is unknown. Among the products tested,
the source of interferon and amount of glycosylation differ.
Some preparations were derived from human lymphoblas-
toid or leukocyte cells, while others were recombinantly
produced in Escherichia coli or mammalian cell culture.
We do not know the importance of this observation with
respect to possible antiviral mechanisms of the interferons
against SARS-CoV or potential clinical implications of
these differences. 
This study describes rapid screening of commercially
available compounds for extension into in vivo research.
Evidence of activity and data from in vitro studies, howev-
er, cannot be easily correlated with clinical performance but
rather present promising candidates for follow-up studies.
Definite recommendations on anti–SARS-CoV activity of
compounds in humans can only be made in the in vivo set-
ting. In conclusion, interferon β-1b, α-n1, α-n3, and human
leukocyte interferon α exhibit antiviral activity in an in
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Figure 2. Dose-response curves for Alferon (A), Betaferon (B), and Multiferon (C) as determined by plaque reduction assays. IC50 (50%
inhibitory concentration) and IC95 (95% inhibitory concentration) values were calculated by using the fitted functions describing the curves. vitro model and are potential drugs for in vivo research and
clinical management of SARS-CoV infection.
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